SVB Leerink Upgrades Regeneron Pharma (REGN) to Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/14/2026
- Nasdaq ends sharply lower as hot inflation data stirs rate-hike worries
- Oil prices gain on attacks in Saudi Arabia, Iran's new tactics to target tankers
- U.S. consumer prices rise by 3.7% year-on-year in September
- Bank of America stock falls on earnings miss
- Netflix cuts 1,000 jobs as streaming giant seeks to boost engagement
Tweet
Share
E-mailGet Alerts REGN Hot Sheet
Price: $778.36 +3.35%
Rating Summary:
30 Buy, 18 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 12 | New: 90
Rating Summary:
30 Buy, 18 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 12 | New: 90
Join SI Premium – FREE
SVB Leerink analyst Andrew Berens upgraded Regeneron Pharma (NASDAQ: REGN) from Market Perform to Outperform with a price target of $976.00 (from $834.00).
For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more ratings news on Regeneron Pharma click here.
Shares of Regeneron Pharma closed at $820.00 yesterday.
You May Also Be Interested In
- Vertical Research Partners Upgrades Lockheed Martin (LMT) to Buy, 'has some core franchises that are likely to prove resilient'
- JFrog (FROG) PT Raised to $125 at UBS
- CrowdStrike (CRWD) PT Raised to $320 at Freedom Broker
Create E-mail Alert Related Categories
Analyst PT Change, Hot Upgrades, UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
